Table 2.
Top-ranking associations of the common variants analysis regarding the performance of the Trail making test.
| Genotype | Case*, N (%) | Control*, N (%) | Model | Case*, N (%) | Control*, N (%) | P value** | OR [95%-CI] | P value adj*** |
|---|---|---|---|---|---|---|---|---|
|
AK8 rs17407084
| ||||||||
|
All cohort, N=229
| ||||||||
| TT | 11 (55.0) | 188 (90.0) | TT | 11 (55.0) | 188 (90.0) | 2.16E-04d | 7.3 [2.7–19.7] | 4.52E-04 |
| TC | 7 (35.0) | 21 (10.0) | TC+CC | 9 (45.0) | 21 (10.0) | |||
| CC | 2 (10.0) | 0 (0.0) | ||||||
|
ZNF382 rs61732180 | ||||||||
|
Males, N=112
| ||||||||
| CC | 3 (27.3) | 65 (64.4) | CC+CT | 6 (54.5) | 97 (96.0) | 3.58E-04r | 20.2 [4.3–95.4] | 2.62E-04 |
| CT | 3 (27.3) | 32 (31.6) | TT | 5 (45.5) | 4 (4.0) | |||
| TT | 5 (45.4) | 4 (4.0) | ||||||
|
AK8 rs17407084 | ||||||||
| Standard risk, N=105 | ||||||||
| TT | 2 (28.6) | 90 (91.8) | TT | 2 (28.6) | 90 (91.8) | 2.44E-04d | 28.1 [4.7–168.8] | 4.40E-04 |
| TC | 4 (57.1) | 8 (8.2) | TC+CC | 5 (71.4) | 8 (8.2) | |||
| CC | 1 (14.3) | 0 (0.0) | ||||||
AK8: Adenylate Kinase 8; ZNF: Zinc Finger Protein 382; FDR: false discovery rate; OR: odds ratio. TT indicates homozygosity for the T allele; TC represents heterozygosity, with one copy of the T allele and one copy of the C allele; CC indicates homozygosity for the C allele.
Participants with and without indicated complications are defined as cases and controls, respectively.
P values are calculated by chi-square or Fisher exact test, as appropriate. The most representative genetic model used is indicated (a: Additive; d: Dominant, r: Recessive).
P value adj: p value from logistic regression adjusted for age at diagnosis, sex, time since the end of treatment, protocol, and treatment variable (chemotherapy only or chemotherapy and radiotherapy).